Researchers have developed a tau-targeting vaccine that could help prevent the progression of Alzheimer’s disease by generating a strong immune response against abnormal tau proteins.

Brain tissue analysis of an animal model has revealed the potential role of immune system dysfunction in the onset and ...

A new blood test identifies a key biomarker for Alzheimer’s disease, which may help make assessing the presence and stage of the disease more accessible in clinical practice.

Scientists see several important uses for staging. For example, it can steer people more precisely to appropriate treatments.

Space, An Early Frontier. When a brain region is tau-negative by SUVR (green arrow, left), spatial extent (dark blue) correlates better with measures of disease severity than does SUVR (light blue).

Voyager is currently assessing VY7523 in a multiple ascending dose trial in patients with early AD and expects initial tau positron emission tomography (PET) imaging data in the second half of 2026.

Veravas, a leader in clinical diagnostics, today announced the general commercial availability of VeraBIND™ Tau, the first blood-ba ...

Women and individuals with a paternal history of Alzheimer disease (AD) have a stronger association between global β-amyloid (Aβ) and tau deposition.

Voyager Therapeutics Inc (VYGR) reports robust cash reserves and potential milestone payments, while advancing key gene ...